immunization with PPV23 within the last year
any confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency
history of allergic disease or reactions likely to be exacerbated by any component of the vaccine
history of allergic disease likely to be stimulated by the vaccination
history or records of immunosuppressive therapy (with the exception of topical corticosteroids) for more than 14 days and within 6 months of vaccination
history or evidence of administration of immunoglobulins and/or any blood products during the study period or within the three months preceding the study vaccine
use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the study vaccine
administration of a vaccine during the period starting one month before the dose of vaccine and ending one month after
pregnancy

NCT02370069_exc_T1
Procedure
immunization
NCT02370069_exc_T2
Drug
PPV23
NCT02370069_exc_T3
Temporal
within the last year
NCT02370069_exc_T4
Condition
immunodeficiency condition
NCT02370069_exc_T5
Qualifier
suspected
NCT02370069_exc_T6
Qualifier
confirmed
NCT02370069_exc_T7
Condition
uman immunodeficiency virus nfection,
NCT02370069_exc_T8
Condition
HIV
NCT02370069_exc_T9
Condition
haematological malignancy
NCT02370069_exc_T10
Condition
congenital immunodeficiency
NCT02370069_exc_T11
Scope
human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency
NCT02370069_exc_T12
Scope
confirmed or suspected
NCT02370069_exc_T13
Condition
allergic disease
NCT02370069_exc_T14
Condition
lergic d actions l
NCT02370069_exc_T15
Scope
allergic disease or reactions
NCT02370069_exc_T16
Qualifier
exacerbated by any component of the vaccine
NCT02370069_exc_T17
Procedure
vaccine
NCT02370069_exc_T18
Condition
allergic disease
NCT02370069_exc_T19
Qualifier
stimulated by the vaccination
NCT02370069_exc_T20
Procedure
vaccination
NCT02370069_exc_T21
Procedure
immunosuppressive therapy
NCT02370069_exc_T22
Procedure
topical corticosteroids
NCT02370069_exc_T23
Negation
exception
NCT02370069_exc_T24
Temporal
more than 14 days and accination
his
NCT02370069_exc_T25
Temporal
within 6 months of vaccination
NCT02370069_exc_T26
Scope
for more than 14 days and within 6 months of vaccination
NCT02370069_exc_T27
Reference_point
vaccination
NCT02370069_exc_T28
Procedure
immunoglobulins
NCT02370069_exc_T29
Procedure
blood products
NCT02370069_exc_T30
Temporal
during the study period
NCT02370069_exc_T31
Temporal
within the three months preceding the study vaccine
NCT02370069_exc_T32
Reference_point
study period
NCT02370069_exc_T33
Reference_point
study vaccine
NCT02370069_exc_T35
Scope
immunoglobulins and/or any blood products
NCT02370069_exc_T36
Scope
during the study period or within the three months preceding the study vaccine
NCT02370069_exc_T37
Procedure
vaccine
NCT02370069_exc_T38
Procedure
drug
NCT02370069_exc_T39
Qualifier
investigational
NCT02370069_exc_T40
Qualifier
non-registered
NCT02370069_exc_T41
Scope
drug or vaccine
NCT02370069_exc_T42
Scope
investigational or non-registered
NCT02370069_exc_T43
Temporal
during the study period
NCT02370069_exc_T44
Temporal
within 30 days preceding the study vaccine
NCT02370069_exc_T45
Reference_point
study period
NCT02370069_exc_T46
Reference_point
study vaccine
NCT02370069_exc_T47
Scope
during the study period or within 30 days preceding the study vaccine
NCT02370069_exc_T48
Procedure
vaccine
NCT02370069_exc_T49
Temporal
during the period starting one month before the dose of vaccine and ending one month after
NCT02370069_exc_T51
Reference_point
the dose of vaccine
NCT02370069_exc_T52
Procedure
vaccine
NCT02370069_exc_T50
Condition
pregnancy